aid: arresto-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/arresto-biosciences.png
name: Arresto Biosciences
description: 'Arresto Biosciences, Inc. was a privately-held, development-stage biotechnology company
  headquartered in Palo Alto, California, focused on medicines to treat fibrotic diseases and cancer by
  targeting enzymes involved in the synthesis of the extracellular matrix. Its lead product was AB0024,
  a humanized monoclonal antibody targeting the human lysyl oxidase-like-2 (LOXL2) protein, then in
  Phase I studies for idiopathic pulmonary fibrosis and advanced solid tumors. Founded circa 2007 and
  backed by Kleiner Perkins Caufield & Byers, HealthCare Ventures, Northgate Capital, DAG Ventures and
  Abbott Biotech Ventures, Arresto was acquired by Gilead Sciences for $225 million; the deal was
  announced December 20, 2010 and had closed by February 2011. The company no longer operates as an
  independent entity, publishes no developer or API surface, and its former domain (arrestobio.com) no
  longer resolves.'
url: https://raw.githubusercontent.com/api-evangelist/arresto-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-status: acquired
x-status-detail: 'Acquired by Gilead Sciences (Nasdaq: GILD) for $225 million; announced 2010-12-20,
  closed Q1 2011. No longer an independent operating company.'
x-acquisition:
  acquirer: Gilead Sciences, Inc.
  acquirer_slug: gilead-sciences
  amount_usd: 225000000
  announced: '2010-12-20'
  closed_by: '2011-02-21'
  source: https://www.sec.gov/Archives/edgar/data/882095/000129993310004530/exhibit1.htm
x-former-website: http://www.arrestobio.com
x-investors:
- Kleiner Perkins Caufield & Byers
- HealthCare Ventures
- Northgate Capital
- DAG Ventures
- Abbott Biotech Ventures
x-headquarters: Palo Alto, California, United States
x-lead-asset: AB0024, humanized monoclonal antibody targeting LOXL2
x-api-surface: none
x-api-surface-reason: Defunct pre-clinical biotechnology company; never published a public API,
  developer portal, or documentation. Former domain does not resolve (no A/NS records, 2026-07-19).
x-tier: stub
x-tier-reason: defunct-acquired-no-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Drug Discovery
- Oncology
- Fibrosis
- Monoclonal Antibodies
- Acquired
apis: []
common:
- type: LLMsTxt
  url: llms/arresto-biosciences-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: minimal
  artifacts_added: 1
  pass: local-v1